Literature DB >> 3812480

Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant polycystic kidney disease.

J R Gregoire, V E Torres, K E Holley, G M Farrow.   

Abstract

The early v late occurrence of tubular epithelial hyperplasia and the frequency and malignant potential of renal neoplasms in autosomal dominant polycystic kidney disease (ADPKD) are controversial. The kidneys from 87 patients with documented or presumed ADPKD, removed at autopsy (n = 49) or prior to transplantation (n = 38), were thoroughly sectioned and examined. Hyperplastic polyps were found in 90.8% of the patients, even in the absence of renal insufficiency or marked renal enlargement. However, their number was significantly higher in the patients with advanced stages of the disease, and especially in those with a history of dialysis. Hyperplastic polyps were not detected in eight cases, seven of which had no evidence of epithelial hyperplasia, despite thorough examination of multiple sections. A total of 42 neoplasms were observed in 24.1% of the patients. One patient had bilateral low-grade clear cell adenocarcinoma. Another patient had a transitional cell neoplasm. The remaining 39 neoplasms were microscopic adenomas. Neoplasms tended to occur more often in men and older patients. None of these neoplasms had been clinically diagnosed, and no metastasis had occurred. Nonneoplastic mass lesions were observed in two patients: one had malacoplakia and the other had xanthogranulomatous pyelonephritis.

Entities:  

Mesh:

Year:  1987        PMID: 3812480     DOI: 10.1016/s0272-6386(87)80158-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  Uteroglobin promoter-targeted c-MYC expression in transgenic mice cause hyperplasia of Clara cells and malignant transformation of T-lymphoblasts and tubular epithelial cells.

Authors:  A Geick; P Redecker; A Ehrhardt; R Klocke; D Paul; R Halter
Journal:  Transgenic Res       Date:  2001-12       Impact factor: 2.788

Review 2.  Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Vicente E Torres
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 3.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

Review 4.  Epithelial hyperplasia in human polycystic kidney diseases. Its role in pathogenesis and risk of neoplasia.

Authors:  J Bernstein; A P Evan; K D Gardner
Journal:  Am J Pathol       Date:  1987-10       Impact factor: 4.307

Review 5.  Imaging for the prognosis of autosomal dominant polycystic kidney disease.

Authors:  Kyongtae T Bae; Jared J Grantham
Journal:  Nat Rev Nephrol       Date:  2010-02       Impact factor: 28.314

6.  CD2-associated protein in human urogenital system and in adult kidney tumours.

Authors:  Jukka Tienari; Sanna Lehtonen; Eero Lehtonen
Journal:  Virchows Arch       Date:  2005-03-23       Impact factor: 4.064

7.  Abnormal lipid and fatty acid compositions of kidneys from mice with polycystic kidney disease.

Authors:  H M Aukema; T Yamaguchi; H Takahashi; B Celi; B J Holub
Journal:  Lipids       Date:  1992-06       Impact factor: 1.880

8.  Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease.

Authors:  B D Cowley; F L Smardo; J J Grantham; J P Calvet
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  Spontaneous regression of renal cell carcinoma: a pitfall in diagnosis of renal lesions.

Authors:  Y Hamid; D N Poller
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

10.  The homeobox gene Hhex is essential for proper hepatoblast differentiation and bile duct morphogenesis.

Authors:  Michael P Hunter; Christine M Wilson; Xiaobing Jiang; Rong Cong; Hemaxi Vasavada; Klaus H Kaestner; Clifford W Bogue
Journal:  Dev Biol       Date:  2007-05-25       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.